Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors Nov 16, 2021
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update Nov 8, 2021
Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies Oct 25, 2021
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer Sep 22, 2021
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sep 15, 2021
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom’s Macroglobulinemia Aug 18, 2021
Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131 Aug 16, 2021
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update Aug 9, 2021
